Safety and Efficacy of PDL-0101 in Patients With Hyperlipidemias: a Pilot Study.

This will be an 8 week, multicenter, randomized, double blind, placebo controlled trial. The screening visit will be divided into two parts, a "pre-screen" in-clinic rapid lipid test (Cholestech) followed by a full screening blood draw to be sent to the central reference laboratory (CRL) for subjects meeting the Cholestech inclusion values for TG and LDL (see inclusion criteria below) on the pre-screen test. Subjects who do not meet the pre-screen criteria will be discharged from further participation in the study. Subjects must have pre-screen lipid values of LDL >/=70 mg/dl and triglyceride (TG) >/=180 and </=499. Subjects who meet these Cholestech criteria will have blood drawn for central reference laboratory (CRL) screening testing. For randomization, 80% of the subjects must have TG>/=200 mg/dl to proceed to the next screening step while up to 20% will be allowed to proceed to the next screening step with TG=150-199 mg/dl as long as the LDL is>/=70 mg/dl. Subjects who meet the CRL pre-screen lipid inclusion criteria will return 2-14 days later for the remainder of the full screening procedures. Subjects who meet all screening criteria will be randomized at this visit. Thus, the prescreening and screening-1 visits will occur at the same time and the screening 2 visit will also be the baseline visit. BMI will be calculated but is not a criterion for participation.

Subjects who meet all inclusion and exclusion requirements at the screening 2/baseline visit will be randomized to receive one of the two (2) study products. Randomization will proceed in groups of 5 with 4 subjects having TG between 200-499 mg/dl before randomizing a subject with TG between 150-199 mg/dl. Subjects will return for evaluation 4 and 8 weeks after the baseline visit at which times adverse events (AEs) will be recorded, blood lipid studies will be done and subjects will complete a VAS for product tolerability. Laboratory studies will be drawn after subjects have been sitting for at least 5 minutes.

Inclusion criteria

• Either gender, in general good health, between 25-85 years old
• Serum TG 150-495 mg/dl at screening
• Serum LDL >/= 70 mg/dl at screening
• Not using any other product including drugs, medical foods, neutraceuticals or dietary supplements for control of serum lipids
• Consistent dietary habits
• Women of child bearing potential must use an accepted method of birth control
• Able to read and understand study documents including the Subject Informed Consent Document (Spanish language translation available, if needed)

Exclusion criteria

• serum TG <150 or >495 mg/dl at screening visit
• serum LDL<50 mg/dl at screening visit
• use of any other serum lipid modifying agent (see section 6.0) within 4 weeks of screening visit
• history of any intestinal disease that might interfere with absorption
• history of pancreatitis, inflammatory colitis or prior cholecystectomy
• any active malignancy or history of malignancy, except basal cell carcinoma or cervical carcinoma in situ curatively treated, within 3 years of the screening visit
• screening AST, ALT, alkaline phosphatase, bilirubin >1.3 times the upper limit of normal for the reference laboratory
• serum creatinine >2.0
• uncontrolled diabetes mellitus (glycosylated Hgb >9)
• diabetes mellitus not on stable therapy for at least 2 months
• uncontrolled hypertension (DBP >100, SPB >160)
• unstable angina, congestive heart failure or other uncontrolled cardiac disease
• pregnant or lactating women
• known history of allergies to O-3 fatty acids, carotenoids, vitamin E or fish products
• history of substance abuse or any psychiatric condition that may impair the subject's ability to comply with the study requirements.
• Regular consumption of more than one (1) unit of alcohol daily. For the purposes of this study a unit of alcohol consists of 12 oz. of beer, 6 oz. of wine or 2 oz of hard spirits.
• any medical condition that, in the opinion of the investigator, might put the subject at undue risk or might interfere with the subject's ability to participate in the study
• participation in another clinical trial within 30 days or 6 half lives of the study agent, whichever is longer, of the screening visit